Any feedback?
Literature summary for 3.2.1.35 extracted from
- Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models (2008), Clin. Cancer Res., 14, 3933-3941.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | the codelivery of hyaluronidase enzyme with oncolytic adenoviruses is analysed to determine whether it improves the spread of the virus throughout tumors, thereby leading to a greater overall antitumor efficacy in tumor models: In mice injected with the adenovirus Ad5/35GFP and hyaluronidase (50 U), a significant increase in the number of GFP-expressing cells is observed when compared with animals injected with virus only. When the oncolytic adenoviruses Ad5OV or Ad5/35 OV are codelivered with 50 U of hyaluronidase, a significant delay in tumor progression is observed, which translates into a significant increase in the mean survival time of tumor-bearing mice compared with either of the monotherapy-treated groups. Furthermore, the mice that receive the combination of Ad5/35 OV and hyaluronidase show the best antitumor efficacy | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| hyaluronidase | - |
Homo sapiens |
| rHuPH20 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
